CeloNova BioSciences Announces Accelerated IDE Trial Enrollment Completion For Its COBRA Pzf Coronary Stent System
SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc. announced completion of patient enrollment in the global, multi-center IDE trial for its COBRA PzF stent. Completed enrollment was ahead of schedule and supports submission for FDA approval of the novel COBRA PzF stent with its advanced, nano-thin coating of Polyzene™-F polymer.
“We are excited to have completed this important milestone, with the involvement of outstanding study investigators under the leadership of Principal Investigator Professor Donald Cutlip, MD, of the Harvard Medical School in Boston, Massachusetts and Co-Principal Investigator Professor Sigmund Silber, MD, PhD of the University of Munich, Germany,” stated Martin Landon, CEO of CeloNova BioSciences. “Completion of enrollment ahead of schedule suggests that there is very high interest in the disruptive potential of our stent.”
Help employers find you! Check out all the jobs and post your resume.
“We are excited to have completed this important milestone, with the involvement of outstanding study investigators under the leadership of Principal Investigator Professor Donald Cutlip, MD, of the Harvard Medical School in Boston, Massachusetts and Co-Principal Investigator Professor Sigmund Silber, MD, PhD of the University of Munich, Germany,” stated Martin Landon, CEO of CeloNova BioSciences. “Completion of enrollment ahead of schedule suggests that there is very high interest in the disruptive potential of our stent.”
Help employers find you! Check out all the jobs and post your resume.